The gospel of esophageal cancer patients! The Mersadon PD-1 inhibitor Paboli Zuma is approved for a new adaptation certificate in China.

recently, the world's first approved esophageal cancer immunotherapy drug Paboli zuma (commonly known as "K drug") was approved in China for the evaluation of tumor expression PD-L1 (comprehensive positive score (CPS) s10) through fully validated, local izedogenous end-of-care squamous cell cancer (ESCC) patientsThis is the 5th adaptation certificate approved in China for Paboli Zuma, and it also opens a new journey of immunotherapy in the chinese characteristics of digestive tract tumorsaccount for half of china's esophageal cancer, and has not been available for decades with new drugs
esophageal cancer as one of the cancers with Chinese characteristics, accounting for about half of the world's population and deathsProfessor Shen Lin, Vice President of Beijing Cancer Hospital and China leader of THE KEYNOTE-181 study, talks about the differences between esophageal cancer in China and the global differences: "The difference between esophageal cancer in China and western esophageal cancer, one is pathological type, western esophageal cancer is high, more than 95% of Chinese esophageal cancer is esophageal scaly cancer; China's esophageal cancer 60%-70% found when it is already in the middle and late stage, lost the opportunity to cure surgical excision, the traditional treatment only radiation chemotherapy, and the middle and late patients mostly have difficulty swallowing, malnutrition problems, the effect of chemotherapy is not satisfactory, the patient syllable end of esophageal cancer 5 years survival rate is only about 4.8%"
is precisely because of the difference between Chinese and Western esophageal cancer, many used for esophageal adenocarcinoma good efficacy of chemotherapy or targeted drugs, for esophageal squamous cancer has repeatedly hit the wall, so that esophageal scale cancer for nearly half a century has not been on the market, China's esophageal cancer urgently need sehaving can improve long-term survival benefits of new drugs new treatmentsthe world's first immunotherapy for esophageal squamous cancer was approved in China2018, won a Nobel Prize for its unique treatment mechanism, which recognizes and kills tumor cells by waking up the immune system, and is used in the long-term survival of a variety of cancers to "cure" the promising treatment2019, the immunotherapy representative, mercadodon PD-1 inhibitor K, was approved by the FDA for the treatment of tumor expression PD-L1 recurrent locally advanced or metastatic esophageal scale cancer, opening a new chapter in esophageal cancer immunotherapyJune 2020, K drug was approved by the State Drug Administration for the treatment of esophageal scale cancer patientseven more surprising, K drug in China's esophageal cancer patients more prominent efficacy, can be said to be for Chinese patients "tailored" breakthrough treatment:Tumor size: The objective remission rate of immunotherapy in patients with tumor expression PD-L1 esophageal cancer is close to 4 times that of standard chemotherapy, and some patients can achieve complete remission, which means that some patients with immunotherapy can completely disappear: The median total survival time of patients with tumor expression PD-L1 esophageal cancer reached 12 months, far more than the 5.3 months of the chemotherapy group, and reduced the risk of disease death by 66%long-term survival and prognosis: Tumor expression PD-L1 esophageal cancer patients treated for 1 year, more than half of patients with pabolizumab can survive, and the incidence of adverse reactions above 3 levels of K drug is half of chemotherapy, meaning better long-term prognosisbased on these data, K-drug became the only NCCN (National Comprehensive Cancer Network) guidelines and CSCO (Chinese Society of Clinical Oncology) esophagus cancer guidelines recommended for recurrent esophageal scale cancer immunotherapy immunotherapy has opened a new chapter for esophageal cancer in China
so far, K drug has been approved in the world 24 certificates of adaptation, 5 domestic adaptation certificates, for more patients to provide trusted immunotherapy And K drug is the only domestic approved PD-L1 accompanying diagnosis of immunotherapy, generally speaking, the higher the expression of PD-L1, the higher the probability of tumor remission and long-term survival from immunotherapy Professor Shen Lin said: "There are huge differences in esophageal cancer treatment, esophageal scale cancer traditional available drugs are less, Paboli zuma is the first in China and western esophageal cancer to verify this difference and show long-term survival improvement in patients with esophageal scale cancer in China, is a breakthrough therapy, and PD-L1 testing can help doctors better understand the efficacy and prognosis of patients using immunotherapy, will completely change the treatment pattern of esophageal cancer in China." "
is known that K drug "key to life" patient assistance program will further expand assistance to patients, timely to provide drug assistance to esophageal cancer patients, so that more patients with financial difficulties can also use accurate, safe and reliable treatment drugs expects the first esophageal cancer immunotherapy to provide more chinese esophageal cancer patients with safer, life-extending treatment options, bringing a new hope for real long-term survival benefits.